Genomic data and prostate cancer risk classification: an update

Three different molecular tests have been validated as providing useful data that can help a man and his doctors to come to decisions about the management and treatment of localized prostate cancer. … READ MORE …

Genomic testing for localized prostate cancer: an update

A relatively brief, current, full-text review article by Loeb and Ross is available on the Medscape web site and discusses the three currently available tests for assessment of genomic risk for men with localized forms of prostate cancer. … READ MORE …

Are genomic tests “up to snuff” for routine use in prognosis of prostate cancer risk?

The Intergroupe Coopérateur Francophone de Recherche en Onco-urologie (ICFuro) has just published a review of the available evidence on the clinical validity and utility of six prognostic biomarkers available for the assessment of prostate cancer-related risk. … READ MORE …

Development of a standardized commercial test to “score” patients as eligible for active surveillance

A new paper to be presented at the Genitourinary Prostate Cancer Symposium has proposed development of a standardized method to “score” whether patients are suitable candidates for initial management on active surveillance. … READ MORE …

Prolaris test data change clinician, patient decisions about prostate cancer management

A new paper in the Journal of Urology provides us with some interesting if preliminary information on the ways that genetic/genomic tests of biopsy samples may be affecting first-line treatments for localized forms of prostate cancer. … READ MORE …

Medicare may soon cover Prolaris, Decipher tests for prostate cancer

Both Myriad Genetics and Genome DX Biosciences issued media releases today stating that Medicare contractors have issued draft coverage recommendations for tests used to assess the aggressiveness of prostate cancer based on genetic/genomic analyses of tissue from biopsy and post-surgical samples. … READ MORE …

When test “validation” raises questions about levels of validity

There is something of a fuss emerging about data presented at the American Urological Association annual meeting and a claim that these data imply that Myriad Genetics’ genomic Prolaris test ‘has been “validated” in its ability to predict disease-specific death’. … READ MORE …

The real clinical utility of tests like Prolaris and Oncotype DX in management of prostate cancer

Regular readers (and others) who are interested in gaining more understanding of the potential clinical utility of the new, gene-based prognostic tests for the management of localized prostate cancer will be interested in reading a new article on the Medscape Oncology web site. … READ MORE …

Can Prolaris test accurately predict risk for prostate cancer-specific mortality?

Data to be presented at the upcoming meeting of the American Society of Clinical Oncology addresses the potential of the Prolaris™ test (developed by Myriad Genetics, Inc.) to predict which men being followed under an active surveillance protocol are at greatest risk of dying from prostate cancer at 10 years of follow-up. … READ MORE …

Is CCP testing really the prognostic tool we need?

A new report just published on line in Lancet Oncology is suggesting that the cell cycle progression (CCP) score — a measure of the levels of expression of selected genes that are important to cell growth — may be an important indicator of risk for more aggressive types of prostate cancer. … READ MORE …

Prolaris: prognostically accurate but of limited utility?

According to a media release from  Myriad Genetics, the company’s investigational genetic test (Prolaris™) can accurately predict prostate cancer-specific mortality at 10 years in men known to have clinically localized prostate cancer. … READ MORE …

The data behind the $3,400 test for prostate cancer recurrence

Some days ago we commented on a media release issued by Myriad Genetics which stated that their new PROLARIS™ test “identifies patients at low risk of disease recurrence with 95% certainty.” … READ MORE …

A new, $3,400 test for prostate cancer recurrence

Myriad Genetics has announced the launch of a 46-gene prognostic test which is supposed to be able to determine the risk of prostate cancer recurrence in patients who have undergone a radical prostatectomy. … READ MORE …